NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $25.00 price target on the stock.

Several other brokerages have also issued reports on NRXP. HC Wainwright lifted their price target on shares of NRx Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. D. Boral Capital restated a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, March 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets reiterated a “buy” rating and set a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. Finally, Zacks Research raised NRx Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.00.

NRx Pharmaceuticals Price Performance

Shares of NRXP traded up $0.24 during mid-day trading on Tuesday, hitting $2.01. 743,030 shares of the company’s stock were exchanged, compared to its average volume of 1,048,546. The company has a market cap of $64.03 million, a PE ratio of -0.86 and a beta of 1.97. NRx Pharmaceuticals has a 52 week low of $1.58 and a 52 week high of $3.84. The company has a 50-day simple moving average of $1.94 and a 200 day simple moving average of $2.44.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings data on Monday, March 23rd. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.28. The business had revenue of $0.98 million during the quarter, compared to the consensus estimate of $7.53 million. On average, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Ethos Financial Group LLC bought a new stake in NRx Pharmaceuticals during the third quarter worth about $39,000. Sjbenen Advisory LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $41,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the period. Global Retirement Partners LLC bought a new stake in shares of NRx Pharmaceuticals during the 4th quarter worth approximately $107,000. Finally, Two Sigma Investments LP boosted its position in shares of NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.